MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 202701 | Name: Resveratrol
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Resveratrol (also known as SRT-501) is a phytoalexin derived from grapes and other food products with antioxidant and potential chemopreventive activities. Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity); mediates anti-inflammatory effects and inhibits cyclooxygenase and hydroperoxidase functions (anti-promotion activity); and induces promyelocytic leukemia cell differentiation (anti-progression activity), thereby exhibiting activities in three major steps of carcinogenesis. This agent may inhibit TNF-induced activation of NF-kappaB in a dose- and time-dependent manner.

Chemical Structure

Resveratrol
Resveratrol
CAS#501-36-0

Theoretical Analysis

MedKoo Cat#: 202701

Name: Resveratrol

CAS#: 501-36-0

Chemical Formula: C14H12O3

Exact Mass: 228.0786

Molecular Weight: 228.24

Elemental Analysis: C, 73.67; H, 5.30; O, 21.03

Price and Availability

Size Price Availability Quantity
1g USD 150.00 Ready to ship
5g USD 250.00 Ready to ship
10g USD 350.00 Ready to ship
25g USD 550.00 Ready to ship
50g USD 850.00 Ready to ship
100g USD 1,250.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
trans-Resveratrol; SRT501; SRT-501; SRT 501; RM1812; RM-1812; RM 1812; CA1201; CA-1201; CA 1201; Resvida; Vineatrol 20M.
IUPAC/Chemical Name
(E)-5-(4-hydroxystyryl)benzene-1,3-diol
InChi Key
LUKBXSAWLPMMSZ-OWOJBTEDSA-N
InChi Code
InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
SMILES Code
OC1=CC(/C=C/C2=CC=C(O)C=C2)=CC(O)=C1
Appearance
Light yellow solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO and ethanol
Shelf Life
>10 years if stored properly
Drug Formulation
This drug may be formulated in DMSO and ethanol
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Resveratrol new formulation: Sirtris Pharmaceuticals  is currently deeloping a resveratrol formulation, called SRT501, which is a proprietary formulation of resveratrol, a polyphenolic phytoalexin derived from grapes and other food products with potential antioxidant, anti-obesity, antidiabetic and chemopreventive activities. Resveratrol may activate sirtuin subtype 1 (SIRT-1). SIRT1 activation has been reported to inhibit tumorigenesis and tumor cell proliferation. SIRT-1 is a member of the silent information regulator 2 (SIR2) (or sirtuin) family of enzymes that plays an important role in mitochondrial activity and acts as a protein deacetylase. SIRT1 appears to be involved in the regulation of numerous transcription factors such as Nf-kB and p53. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus) .   SRT501 is Sirtris's  proprietary formulation of resveratrol with improved bioavailability. In Phase I human clinical trials, SRT501 was found to be safe and well tolerated. In Phase II human clinical trials, SRT501 also lowered glucose and improved insulin sensitivity in patients with Type 2 Diabetes. Sirtris are currently testing SRT501 in a Phase II trial in oncology; new patient enrollment is currently suspended. see http://www.sirtrispharma.com/pipeline-SRT501.html.      
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#EOS10822
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Resveratrol has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase (IC50 0.8 nM), IKKβ (IC50 1 μM) , DNA polymerase α (IC50 3.3 μM), and DNA polymerase δ (5 μM). Resveratrol also is a specific SIRT1 activator and is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
In vitro activity:
By analyzing a variety of inflammatory, neuroprotective, and metabolic aspects, resveratrol was observed to reduce inflammasome activity, increase the release of insulin-like growth factor 1, decrease glucose uptake, lower mitochondrial activity, and attenuate cellular metabolism in a 1H NMR-based analysis of whole-cell extracts. This study demonstrates that resveratrol might provide protection from persisting neuroinflammation. Reference: Antioxidants (Basel). 2023 Jun 9;12(6):1248. https://pubmed.ncbi.nlm.nih.gov/37371977/
In vivo activity:
This study demonstrated that resveratrol relieved electrophysiological injury of retinas and inhibited retinal ganglion cell apoptosis in diabetic mice. Low-dose resveratrol can ameliorate diabetes-induced retinal ganglion cell degeneration via the TyrRS/c-Jun pathway. Resveratrol can promote TyrRS nuclear translocation and bind to c-Jun, downregulating c-Jun phosphorylation and downstream pro-apoptotic genes. Reference: Invest Ophthalmol Vis Sci. 2023 Jun 1;64(7):2. https://pubmed.ncbi.nlm.nih.gov/37261387/
Solvent mg/mL mM
Solubility
DMSO 50.0 219.10
Ethanol 50.0 219.10
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 228.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Schlotterose L, Pravdivtseva MS, Ellermann F, Jansen O, Hövener JB, Sönnichsen FD, Cossais F, Lucius R, Hattermann K. Resveratrol Mitigates Metabolism in Human Microglia Cells. Antioxidants (Basel). 2023 Jun 9;12(6):1248. doi: 10.3390/antiox12061248. PMID: 37371977; PMCID: PMC10294838. 2. Mohd A, Zainal N, Tan KK, AbuBakar S. Resveratrol affects Zika virus replication in vitro. Sci Rep. 2019 Oct 4;9(1):14336. doi: 10.1038/s41598-019-50674-3. PMID: 31586088; PMCID: PMC6778103. 3. Xiao K, Ma XH, Zhong Z, Zhao Y, Chen XH, Sun XF. Low-Dose Trans-Resveratrol Ameliorates Diabetes-Induced Retinal Ganglion Cell Degeneration via TyrRS/c-Jun Pathway. Invest Ophthalmol Vis Sci. 2023 Jun 1;64(7):2. doi: 10.1167/iovs.64.7.2. PMID: 37261387; PMCID: PMC10241309. 4. Feng H, Mou SQ, Li WJ, Zhang N, Zhou ZY, Ding W, Bian ZY, Liao HH. Resveratrol Inhibits Ischemia-Induced Myocardial Senescence Signals and NLRP3 Inflammasome Activation. Oxid Med Cell Longev. 2020 Aug 25;2020:2647807. doi: 10.1155/2020/2647807. PMID: 32908628; PMCID: PMC7468658.
In vitro protocol:
1. Schlotterose L, Pravdivtseva MS, Ellermann F, Jansen O, Hövener JB, Sönnichsen FD, Cossais F, Lucius R, Hattermann K. Resveratrol Mitigates Metabolism in Human Microglia Cells. Antioxidants (Basel). 2023 Jun 9;12(6):1248. doi: 10.3390/antiox12061248. PMID: 37371977; PMCID: PMC10294838. 2. Mohd A, Zainal N, Tan KK, AbuBakar S. Resveratrol affects Zika virus replication in vitro. Sci Rep. 2019 Oct 4;9(1):14336. doi: 10.1038/s41598-019-50674-3. PMID: 31586088; PMCID: PMC6778103.
In vivo protocol:
1. Xiao K, Ma XH, Zhong Z, Zhao Y, Chen XH, Sun XF. Low-Dose Trans-Resveratrol Ameliorates Diabetes-Induced Retinal Ganglion Cell Degeneration via TyrRS/c-Jun Pathway. Invest Ophthalmol Vis Sci. 2023 Jun 1;64(7):2. doi: 10.1167/iovs.64.7.2. PMID: 37261387; PMCID: PMC10241309. 2. Feng H, Mou SQ, Li WJ, Zhang N, Zhou ZY, Ding W, Bian ZY, Liao HH. Resveratrol Inhibits Ischemia-Induced Myocardial Senescence Signals and NLRP3 Inflammasome Activation. Oxid Med Cell Longev. 2020 Aug 25;2020:2647807. doi: 10.1155/2020/2647807. PMID: 32908628; PMCID: PMC7468658.
 1: Švajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol. 2012 Jun;31(3):202-22. Review. PubMed PMID: 22587021. 2: Whitlock NC, Baek SJ. The anticancer effects of resveratrol: modulation of transcription factors. Nutr Cancer. 2012;64(4):493-502. Epub 2012 Apr 6. Review. PubMed PMID: 22482424; PubMed Central PMCID: PMC3349800. 3: Juan ME, Alfaras I, Planas JM. Colorectal cancer chemoprevention by trans-resveratrol. Pharmacol Res. 2012 Jun;65(6):584-91. Epub 2012 Mar 28. Review. PubMed PMID: 22465196. 4: Turan B, Tuncay E, Vassort G. Resveratrol and diabetic cardiac function: focus on recent in vitro and in vivo studies. J Bioenerg Biomembr. 2012 Apr;44(2):281-96. Review. PubMed PMID: 22437738. 5: Timmers S, Auwerx J, Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY). 2012 Mar;4(3):146-58. Review. PubMed PMID: 22436213; PubMed Central PMCID: PMC3348475. 6: Aluyen JK, Ton QN, Tran T, Yang AE, Gottlieb HB, Bellanger RA. Resveratrol: potential as anticancer agent. J Diet Suppl. 2012 Mar;9(1):45-56. Review. PubMed PMID: 22432802. 7: Nakata R, Takahashi S, Inoue H. Recent advances in the study on resveratrol. Biol Pharm Bull. 2012;35(3):273-9. Review. PubMed PMID: 22382311. 8: Lopez-Lluch G, Cruz-Calvo SS, Navas P. Resveratrol in cancer: cellular and mitochondrial consequences of proton transport inhibition. Curr Pharm Des. 2012;18(10):1338-44. Review. PubMed PMID: 22360556. 9: Li H, Xia N, Förstermann U. Cardiovascular effects and molecular targets of resveratrol. Nitric Oxide. 2012 Feb 15;26(2):102-10. Epub 2012 Jan 4. Review. PubMed PMID: 22245452. 10: Scott E, Steward WP, Gescher AJ, Brown K. Resveratrol in human cancer chemoprevention--choosing the 'right' dose. Mol Nutr Food Res. 2012 Jan;56(1):7-13. doi: 10.1002/mnfr.201100400. Epub 2011 Oct 7. Review. PubMed PMID: 22218912. 11: Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer's disease. Curr Pharm Des. 2012;18(1):27-33. Review. PubMed PMID: 22211686. 12: Mullin GE. Red wine, grapes, and better health--resveratrol. Nutr Clin Pract. 2011 Dec;26(6):722-3. Review. PubMed PMID: 22205561. 13: Frombaum M, Le Clanche S, Bonnefont-Rousselot D, Borderie D. Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and *NO bioavailability: Potential benefits to cardiovascular diseases. Biochimie. 2012 Feb;94(2):269-76. Epub 2011 Nov 22. Review. PubMed PMID: 22133615. 14: Piotrowska H, Kucinska M, Murias M. Biological activity of piceatannol: leaving the shadow of resveratrol. Mutat Res. 2012 Jan-Mar;750(1):60-82. Review. PubMed PMID: 22108298. 15: Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem. 2012 Mar;113(3):752-9. doi: 10.1002/jcb.23431. Review. PubMed PMID: 22065601. 16: Amri A, Chaumeil JC, Sfar S, Charrueau C. Administration of resveratrol: What formulation solutions to bioavailability limitations? J Control Release. 2012 Mar 10;158(2):182-93. Epub 2011 Sep 25. Review. PubMed PMID: 21978644. 17: Duntas LH. Resveratrol and its impact on aging and thyroid function. J Endocrinol Invest. 2011 Nov;34(10):788-92. Epub 2011 Sep 23. Review. PubMed PMID: 21946130. 18: Chu LM, Lassaletta AD, Robich MP, Sellke FW. Resveratrol in the prevention and treatment of coronary artery disease. Curr Atheroscler Rep. 2011 Dec;13(6):439-46. Review. Erratum in: Curr Atheroscler Rep. 2011 Dec;13(6):508. PubMed PMID: 21870059. 19: Dolinsky VW, Dyck JR. Calorie restriction and resveratrol in cardiovascular health and disease. Biochim Biophys Acta. 2011 Nov;1812(11):1477-89. Epub 2011 Jul 1. Review. PubMed PMID: 21749920. 20: Vang O, Ahmad N, Baile CA, Baur JA, Brown K, Csiszar A, Das DK, Delmas D, Gottfried C, Lin HY, Ma QY, Mukhopadhyay P, Nalini N, Pezzuto JM, Richard T, Shukla Y, Surh YJ, Szekeres T, Szkudelski T, Walle T, Wu JM. What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One. 2011;6(6):e19881. Epub 2011 Jun 16. Review. PubMed PMID: 21698226; PubMed Central PMCID: PMC3116821.